This trial is testing the antibiotic rifaximin for treating microscopic colitis, a condition causing frequent and watery stools. The study involves patients taking the medication regularly over a period of weeks. The goal is to see if it reduces inflammation and improves symptoms by lowering gut bacteria levels. Rifaximin is a non-absorbable antibiotic derived from rifamycin, used to treat various intestinal bacterial infections and inflammatory bowel diseases.